Introduction: Colorectal cancer (CRC) is one of the leading causes of. cancer-related mortality in the Western world. In Spain is the second type. of cancer in incidence and mortality in both sexes and 50% of total. diagnostic cases death. Despite the improvement of diagnostic and treatment. only a few decreases have been observed. About 60% of all patients. diagnosed with CRC will present localized disease, being the surgery the. mainstay therapy. The rest of patients (Duke''s C and D) are diagnosed with. distal metastasis. 5-FU and oxaliplatin based chemotherapy (QT) are the. base of the standard treatment of colorectal cancer patients in both. adjuvant and metastasic setting. Initially, more patients did not respond. to QT treatments and others relapse after a short period of response. In. spite of the clinical relevance of 5-FU, little is known about the. mechanisms of resistance to this drug commonly observed in colorectal. cancer patients. Aim: To identify the genes involved in the mechanism of. resistance to 5-FU in the pluricellular model organisms Caenorhabditis. elegans (C.elegans), and posterior validation of these genes as a markers. of response/sensitivity to 5-FU chemotherapy treatments in tumor series.. Methods and Results: A 5-FU plate toxicity assay has been established. We. are characterizing the ceTS-1 gene, C.elegans homolog of human thymidylate. synthase gene, and temporal and cellular expression patterns during. development are studying in GFP transgenic worms. Different alternative. splicing isoforms are generating in CeTS-1 with unknown biological. implications that we are evaluating. Different phenotypes have been. associated with the worm 5-FU treatment. N2 wild-type worms and
cib-1(
e300). mutant, harboring a point mutation in Thymidilate Synthase gene (Schnabel. R), were synchronized, and both strains of worms were growth at different. drug concentrations and at different times. Profiles of 5-FU response are. being determined in C.elegans Affymetrix microarrays. To identify response. genes (we expected around 100-150 genes) we are performing a feeding double-. stranded RNA-mediated interference (dsRNAi) screening for response genes.. Conclusions: Identification in C. elegans of genes involved in the. resistance/sensitivity to 5-FU drug and later validation of their. predictive value of response in colorectal cancer series may permit to. dispose of the some genetic markers that finally can improve the CRC. patient treatment.. avillanueva@iconcologia.net